Edgar Filing: NOVAVAX INC

THIS FILING IS MADE PURSUANT TO
RULE 424(b)(5) UNDER THE SECURITIES ACT OF 1933
IN CONNECTION WITH REGISTRATION NO. 333-108006

PROSPECTUS SUPPLEMENT
(TO PROSPECTUS DATED NOVEMBER 12, 2003)

4,000,000 SHARES

NOVAVAX, INC.

COMMON STOCK

We are offering on a best efforts all-or-none basis 4,000,000 shares of our
common stock, par value $.01 per share, pursuant to this prospectus supplement.
In connection with this offering, we will pay fees to Lane Capital Markets,
LLC, as the placement agent. See "Plan of Distribution" beginning on page S-14
of this prospectus supplement for more information regarding this arrangement.

Our common stock is traded on the Nasdaq National Market under the symbol NVAX.
On June 30, 2005 the closing price of our common stock as reported on the Nasdaq
National Market was $1.32 per share.

INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. THESE RISKS ARE
DESCRIBED UNDER THE CAPTION "RISK FACTORS" BEGINNING ON PAGE S-6 OF THIS
PROSPECTUS SUPPLEMENT.

Neither the Securities and Exchange Commission nor any state securities
regulators have approved or disapproved of these securities or determined if
this prospectus supplement or the accompanying prospectus is truthful or
complete. Any representation to the contrary is a criminal offense.

---------------------

Per Share Offering
---------- ----------------

Public Offering Price $1.00 $4,000,000

Placement Agent Fee $ .05 $ 200,000

Proceeds, Before Expenses, To Novavax $ .95 $3,800,000

We estimate the total expenses of this offering, excluding the placement agent
fee, will be approximately $150,000. The placement agent is not required to
arrange for the sale of any specific number or dollar amount of the shares of
common stock offered by this offering, but will use its best efforts to sell the
shares of common stock offered. The offering will end on or prior to July 1,
2005. Pursuant to an escrow agreement among us, the placement agent and an
escrow agent, certain funds received in payment for the shares sold in this
offering will be deposited into a non-interest-bearing escrow account and held
until we and the placement agent notify the escrow agent that the offering has
closed, indicating the date on which the shares are to be delivered to the
purchasers and the proceeds are to be delivered to us. In the event that less
than $4,000,000 is deposited in the escrow account by July 1, 2005, this
offering will terminate. If this offering terminates, all funds received from
investors and held by escrow agent will be returned, without interest.

---------------------

LANE CAPITAL MARKETS

---------------------

June 30, 2005

TABLE OF CONTENTS

PROSPECTUS SUPPLEMENT
Page
----

Summary.................................................. S-3
The Offering............................................. S-4
Summary Consolidated Financial Data...................... S-5
Risk Factors............................................. S-6
Special Note Regarding Forward Looking Statement......... S-12
Use of Proceeds.......................................... S-13
Dilution................................................. S-13
Plan of Distribution..................................... S-14
Legal Matters............................................ S-15

PROSPECTUS
Page
----

Prospectus Summary....................................... 3
Risk Factors............................................. 6
About this Prospectus.................................... 14
Special Note Regarding Forward-Looking Statements........ 15
Use of Proceeds.......................................... 16
Plan of Distribution..................................... 17
Description of Our Capital Stock......................... 20
Dividend Policy.......................................... 22
Legal Matters............................................ 22
Experts.................................................. 22
Where You Can Find More Information...................... 22
Incorporation of Certain Information by Reference........ 23

---------------------

This prospectus supplement is a supplement to the accompanying prospectus
that is also a part of this document. This prospectus supplement and the
accompanying prospectus are part of a shelf registration statement that we filed
with the Securities and Exchange Commission. Under the shelf registration
process, we may offer from time to time shares of our common stock up to an
aggregate amount of $50,000,000, of which this offering is a part. We previously
sold 4,500,000 shares of common stock for net proceeds of approximately $25.9
million. In the accompanying prospectus, we provide you with a general
description of the securities we may offer from time to time under our shelf
registration statement. In this prospectus supplement, we provide you with
specific information about the shares of our common stock that we are selling in
this offering. This prospectus supplement and the accompanying prospectus and
the documents incorporated by reference herein and therein include important
information about us, our common stock being offered and other information you
should know before investing. This prospectus supplement also adds, updates, and
changes information contained in the accompanying prospectus. You should read
both this prospectus supplement and the accompanying prospectus as well as the
additional information described under "Where You Can Find More Information"
before investing in shares of our common stock.

You should rely only on information contained in this prospectus
supplement, the accompanying prospectus and the documents we incorporate by
reference in this prospectus supplement and the accompanying prospectus. We have
not authorized anyone to provide you with information that is different. We are
offering to sell and seeking offers to buy shares of our common stock only in
jurisdictions where such offers and sales are permitted. The information
contained in this prospectus supplement and the accompanying prospectus is
accurate only as of their respective dates, regardless of the time of delivery
of this prospectus supplement and the accompanying prospectus or of any sale of
our common stock.

---------------------

In this prospectus supplement, "we," "us" and "our" and "our company"
refer to Novavax, Inc., together with its subsidiaries, unless the context
otherwise requires.

S-2

SUMMARY

This summary highlights selected information contained elsewhere or
incorporated by reference in this prospectus supplement, and may not contain all
of the information that is important to you. For a more complete understanding
of this offering, you should read this entire document carefully and the
accompanying prospectus before deciding to invest in our common stock, including
the "Risk Factors" section below, and those additional documents to which we
refer you. See "Where You Can Find More Information" on page 22.

OUR BUSINESS

We are a specialty biopharmaceutical company engaged in the research,
development and commercialization of proprietary products focused on women's
health and infectious diseases. We sell, market, and distribute a line of
prescription pharmaceuticals and prenatal vitamins. Our proprietary topical
micellar nanoparticle (MNP) drug delivery platform , our principal technology
platform, involves the use of patented oil and water nanoemulsions which can be
used as vehicles for the delivery of a wide variety of drugs and other
therapeutic products, including hormones. On October 9, 2003, our lead topical
product candidate, ESTRASORB, the first topical emulsion for estrogen therapy,
was approved for marketing by the Food and Drug Administration. The FDA approved
ESTRASORB for the treatment of moderate to severe vasomotor symptoms (hot
flashes) associated with menopausal women.

In addition to marketing ESTRASORB, we continue to focus our efforts on
the development of additional compounds that use our proprietary topical MNP
drug delivery platform that we believe have a high probability of technical
success and that have a large market potential. As part of our research and
development efforts, we intend to file two Investigational New Drug Applications
(INDs) with the FDA within the fourth quarter of 2005 and the first quarter of
2006 for two non-hormone product candidates. The following table summarizes our
most advanced drug candidates currently in clinical or preclinical development:

[GRAPHIC TABLE OMITTED]

S-3

We plan to continue leveraging our technologies to develop these and other new
product candidates to be marketed by the Company, co-promoted or licensed to
other drug companies. While our main therapeutic areas of concentration are
women's health and infectious diseases, we believe our technologies can be
applied more broadly.

Our principal executive offices are located at 508 Lapp Road, Malvern,
Pennsylvania 19355. Our telephone number is (484) 913-1200 and our Internet
address is www.novavax.com.

THE OFFERING

Common stock offered in this offering .................... 4,000,000 shares

Common stock to be outstanding after
this offering .......................................... 43,553,876 shares

Use of proceeds .......................................... For our internal research and development
programs, such as preclinical and clinical
testing and studies of our product candidates
and the development of new technologies; and
general working capital. See "Use of Proceeds"
on page S-14.

Nasdaq National Market symbol ............................ NVAX

The information above is based on 39,553,876 shares of common stock outstanding
as of June 29, 2005. It does not include:

o 6,046,542 shares of common stock issuable upon the exercise of stock
options outstanding as of June 29, 2005 at a weighted average exercise
price of $4.73 per share;

o 70,000 shares of common stock issuable upon the exercise of warrants
outstanding as of June 29, 2005 at a weighted average exercise price of
$6.00 per share;

o 2,271,275 shares of common stock reserved for future awards under our
2005 Stock Incentive Plan as of June 29, 2005; and

o 5,691,057 shares of common stock issuable upon the conversion of
$35.0 million aggregate principal amount of 4.75% convertible notes due
July 15, 2009, plus 474,147 shares based on gross proceeds of the
offering, as a result of anti-dilution provisions in the notes.

S-4

SUMMARY CONSOLIDATED FINANCIAL DATA

The historical consolidated financial data presented below as of and for
each of the periods ended December 31, 2004, 2003 and 2002 were derived from our
audited consolidated financial statements. The summary consolidated financial
data is only a summary and should be read in conjunction with our consolidated
financial statements and related notes that we incorporate by reference in this
prospectus supplement. For copies of the financial information we incorporate by
reference, see "Where You Can Find More Information".

Information as of and for the three months ended March 31, 2005 and 2004
has been derived from our consolidated financial statements, which are unaudited
but which in the opinion of management have been prepared on the same basis as
the audited consolidated financial statements and include all adjustments
necessary (consisting of normal recurring adjustments) for a fair presentation
of the results for such periods. The results of operations for the three months
ended March 31, 2005 are not necessarily indicative of the results to be
expected for the entire year ending December 31, 2005 or any future period.

(Amounts in Thousands, Except Share and Per Share Information)
--------------------------------------------------------------

Three months ended
March 31, Years ended December 31,
-------------------------- ------------------------------------------
2005 2004 2004 2003 2002
---------- ---------- ---------- ---------- ----------
(unaudited) (unaudited)

STATEMENT OF OPERATIONS DATA:
Revenues ...................................... $ 719 $ 2,197 $ 8,260 $ 11,785 $ 15,005
Loss from operations .......................... (8,417) (4,896) (24,464) (16,054) (21,558)
Net loss ...................................... (8,886) (5,258) (25,920) (17,273) (22,697)
Per share information:
Basic and diluted net loss per share .......... $ (0.22) $ (0.15) $ (0.70) $ (0.58) $ (0.93)
Weighted average number of
shares outstanding .......................... 39,553,876 34,722,402 36,926,034 29,852,797 24,433,868

As of March 31, As of December 31,
-------------------------- ------------------------------------------
2005 2004 2004 2003 2002
---------- ---------- ---------- ---------- ----------
(unaudited (unaudited)
BALANCE SHEET DATA:

Total current assets .......................... $ 13,573 $ 26,620 $ 23,937 $ 32,062 $ 6,242
Working capital ............................... 7,443 21,843 15,361 27,226 378
Total assets .................................. 66,578 77,800 77,993 84,159 57,505
Convertible debt .............................. 35,000 40,000 35,000 40,000 40,000
Stockholders equity ........................... $ 24,395 $ 30,750 $ 33,281 $ 35,944 $ 8,073

S-5

RISK FACTORS

Investing in our common stock involves a high degree of risk. You should
carefully consider the following risk factors and all other information
contained in this prospectus supplement and the accompanying prospectus and
incorporated by reference into the accompanying prospectus before purchasing our
common stock. The risks and uncertainties described below are not the only ones
facing us. Additional risks and uncertainties that we are unaware of, or that we
currently deem immaterial, also may become important factors that affect us. If
any of the following risks occur, our business, financial condition or results
of operations could be materially and adversely affected. In that case, the
trading price of our common stock could decline, and you may lose some or all of
your investment.

RISKS RELATED TO OUR BUSINESS

THE PRESCRIPTION TRENDS FOR ESTRASORB HAVE NOT MET OUR EXPECTATIONS AND WE
MAY FACE ADDITIONAL RISKS AS WE EXPAND OUR RESEARCH AND DEVELOPMENT
CAPABILITIES.

ESTRASORB was approved for commercial sale by the FDA in October 2003 and
commercially launched in June 2004. To date, the prescription trends for
ESTRASORB have not met our expectations. Many factors have affected and could
continue to affect our ability to successfully commercialize ESTRASORB,
including:

o our inability to timely and effectively promote and sell ESTRASORB so
that ESTRASORB gains a meaningful share of the estrogen therapy market,
which currently is dominated by Premarin(R), an oral estrogen tablet
sold by Wyeth; estrogen patches sold by several companies including
Novartis Pharma AG and Berlex Laboratories, Inc.; and gels currently
sold by Solvay Pharmaceuticals, Inc;.

o our inability to manufacture ESTRASORB at acceptable gross margins;

o the inability to obtain coverage and favorable reimbursement rates for
ESTRASORB from insurers and other third-party payors; and

o the market acceptance of physicians and patients of this new technology.

In addition to the marketing risks of ESTRASORB, we are in the process of
expanding our research and development capabilities in an effort to build upon
the strength of our proprietary topical micellar nanoparticle drug (MNP)
delivery platform. We cannot predict whether we will encounter problems with the
implementation of our modified business strategy, including the delay or
suspension of clinical trials or delay the analysis of data derived from them. A
number of events could delay our development efforts and negatively impact our
ability to obtain regulatory approval for, and to market and sell, a particular
drug candidate.

AFTER THE CONSUMMATION OF THIS OFFERING, WITHOUT THE INFUSION OF
ADDITIONAL CAPITAL, WE WILL ONLY HAVE SUFFICIENT FUNDS TO CONTINUE OPERATIONS
TO THE END OF 2005 AND WILL NOT HAVE SUFFICIENT LIQUIDITY TO AVOID A "GOING
CONCERN" QUALIFICATION FROM OUR AUDITORS FOR FISCAL YEAR 2006.

Our auditors issued a "going concern" opinion for our financial statements
for the year ended December 31, 2004. Even after the consummation of this
offering we will only have sufficient funds to continue operations to the end
of 2005, and we will not have sufficient liquidity to avoid a "going concern"
qualification from our auditors for the fiscal year 2006, unless we are able to
enter into subsequent strategic alliances with third parties which result in
the infusion of capital, or raise additional capital through public or private
equity, this year.

WE HAVE LIMITED FINANCIAL RESOURCES AND WE ARE NOT CERTAIN THAT WE WILL BE
ABLE TO OBTAIN FINANCING TO MAINTAIN OUR OPERATIONS OR TO FUND THE DEVELOPMENT
OF FUTURE PRODUCTS.

In the near term we will not generate revenues from product sales in an
amount sufficient to fund our operations, and we will require additional funds
to maintain our operations, continue our research and development programs,
commence future preclinical and clinical trials, seek regulatory approvals,
establish commercial-scale manufacturing capabilities, and market our products.
We will seek such additional funds through public or private equity or debt
financings, collaborative arrangements and other sources. We cannot be certain
that adequate additional funding will be available to us on acceptable terms, if
at all. If we cannot raise the additional funds required for our anticipated
operations, we may be required to delay significantly, reduce the scope of or
eliminate one or more of our research or development programs, downsize our
selling, marketing, general and administrative infrastructure or programs, or
seek alternative measures to avoid insolvency, including arrangements with
collaborative partners or others that may require us to relinquish rights to
certain of our technologies, product candidates or products. If we raise
additional funds through future offerings of shares of our common stock or other
securities, such offerings would cause dilution of existing stockholders'
percentage ownership in the Company. These future offerings also could have a
material and adverse effect on the price of our common stock.

S-6

WE FACE SUBSTANTIAL COMPETITION IN CONNECTION WITH THE SALE OF ESTRASORB,
OUR OTHER PRODUCTS AND OUR PRODUCT CANDIDATES.

We compete with numerous other companies worldwide that have developed or
are developing products that compete or may compete with ESTRASORB, our other
currently marketed products and our product candidates. These competitors
include both large and small pharmaceutical companies, biotechnology firms,
universities and other research institutions. We may not succeed in developing
technologies and products that are more effective than those being developed by
our competitors.

Many large companies currently produce and sell estrogen products for
clinical indications identical to those for ESTRASORB. Currently, the oral and
patch product segments account for approximately 75% and 15% of the market,
respectively, according to 2004 Verispan data. Wyeth commits significant
resources to the sale and marketing of its product, Premarin(R), in order to
maintain its market leadership position. Several other companies compete in the
estrogen category including Berlex, Novartis and Solvay. Recently, Solvay
introduced an ethanol-based gel product, Estrogel, that is directly competitive
with ESTRASORB.

These and other products sold by our competitors have all achieved a
degree of market penetration superior to ESTRASORB. ESTRASORB competes in the
United States for market share with these products and we cannot guarantee that
we will be able to effectively promote ESTRASORB against these competitive
products. In order to effectively compete, we have and may continue to make
substantial investments in sales and marketing and may have to partner with one
or more established companies that have greater financial resources and
marketing expertise. Many of these products are sold by companies with greater
resources and experience and there is no assurance that we will be successful in
gaining significant market share for ESTRASORB or in earning a return on our
investment in ESTRASORB or our product candidates, if approved.

Our technologies and products may be rendered obsolete or noncompetitive as
a result of products introduced by our competitors. Our vitamin products have
faced sustained and increasing generic competition which recently has resulted
in declining sales volumes and a high volume of returns for this product line.
Most of our competitors have substantially greater financial and technical
resources, production and marketing capabilities, and related experience which
may enable them to develop, manufacture and market their products more
successfully and at a lower cost. In addition, many of our competitors have
significantly greater experience in conducting preclinical testing and clinical
trials of human pharmaceuticals and obtaining regulatory approvals to market
such products. Accordingly, our competitors may succeed in obtaining FDA
approval for products more rapidly than we will, which may give them an
advantage in achieving market acceptance of their products.

WE HAVE A HISTORY OF LOSSES AND OUR FUTURE PROFITABILITY IS UNCERTAIN.

Our expenses have exceeded our revenues since our formation in 1987, and our
accumulated deficit at December 31, 2004 was $130.7 million. Our net revenues
for the last three years were $8.3 million in 2004, $11.8 million in 2003 and
$15.0 million in 2002. For the three months ended March 31, 2005 and 2004, our
revenues were $719,000 and $2.2 million, respectively. We cannot be certain when
or if we will generate substantial revenues from the sale of ESTRASORB. We have
received a limited amount of product-related revenue from research contracts,
licenses and agreements to provide vaccine products, services and adjuvant
technologies. We cannot be certain that we will be successful in entering into
strategic alliances or collaborative arrangements with other companies that will
result in other significant revenues to offset our expenses. Our net losses for
the last three years were $25.9 million in 2004, $17.3 million in 2003 and $22.7
million in 2002, while they were $8.9 million and $5.3 million for the three
months ended March 31, 2005 and 2004, respectively.

Our losses have resulted from research and development expenses, sales and
marketing expenses for ESTRASORB, protection of our intellectual property and
other general operating expenses. Our losses increased due to the launch of
ESTRASORB as we expanded our manufacturing capacity and sales and marketing
capabilities, and may increase as and when we conduct additional and larger
clinical trials for our product candidates. Therefore, we expect our cumulative
operating loss to increase until such time, if ever, product sales, licensing
fees and royalty payments generate sufficient revenue to fund our continuing
operations. We cannot

S-7

predict when, if ever, we might achieve profitability and cannot be certain that
we will be able to sustain profitability, if achieved.

Over the past year we have allocated a significant portion of our sales
force's time to the sales and marketing of ESTRASORB and, consequently, the
sales of our other women's health products has been adversely affected. The
costs of maintaining our own sales force to market our current products
including ESTRASORB currently exceed product revenues. If we continue to market
ESTRASORB or any of our current or future products directly, significant
additional expenditures and management resources will be required to sustain the
size of our internal sales force.

WE MAY NEED ADDITIONAL MANUFACTURING CAPABILITY TO COMMERCIALIZE OUR
PRODUCTS.

We currently manufacture ESTRASORB within a facility of Cardinal Health in
Philadelphia, Pennsylvania. Cardinal Health provides packaging services for
ESTRASORB that we manufacture in their facility. In early 2004, we completed the
build-out of the facility to meet FDA requirements and installed manufacturing
equipment for commercial production. We have been successful in manufacturing
for our current commercial requirements; however, we have limited experience
with the large capacity manufacturing which may be required for the commercial
sale of ESTRASORB or future products. Although we have had the ability to
produce the limited quantities of products needed to support our current
research and development programs and clinical trials (including utilizing
contract manufacturing organizations), we may need more production capacity for
larger, later-stage clinical studies and commercial sales. Our potential
products may be too difficult or costly to manufacture on a large scale, to
develop into commercially viable products, or to market.

In the near term, we intend to continue manufacturing ESTRASORB only in the
Philadelphia facility. We may determine to qualify an additional site or sites
for the manufacture of ESTRASORB if our production requirements increase or we
have opportunities to improve our cost of sales. If we are unable to utilize the
Philadelphia facility to manufacture ESTRASORB prior to our qualification of a
second site, however, we would not have immediate access to ESTRASORB and would
be required to reestablish our validation process at a different facility, which
could cause us to lose sales of ESTRASORB and would adversely affect our
business.

We currently utilize third-party contract manufacturers to manufacture our
other products. Any contract manufacturer's facility that we may use, including
the Cardinal Health facility, must adhere to the FDA's regulations on current
good manufacturing practices, which are enforced by the FDA through its
facilities inspection program. These facilities are subject to periodic
inspection by the FDA. The manufacture of products at these facilities will be
subject to strict quality control testing and record-keeping requirements. If
compliance issues exist at these facilities, thereby interfering with the
manufacture of our products, we would be required to seek alternative
manufacturing arrangements. There can be no assurance that we would be able to
enter into alternative manufacturing arrangements at commercially acceptable
rates, if at all. Moreover, the manufacturers we use may not provide sufficient
quantities of product to meet our specifications or our delivery, cost and other
requirements.

If we decide to manufacture our own products, we will need to acquire
additional manufacturing facilities and improve our manufacturing technology.
Establishing additional manufacturing facilities will require us to spend
substantial funds, hire and retain a significant number of additional personnel
and comply with extensive regulations applicable to such facilities in the
United States and abroad, including the current good laboratory practices and
good manufacturing practices required by the FDA. If we elect or are required to
manufacture our own products, we risk the possibility that we may not be able to
do so in a timely fashion at acceptable quality and prices or in compliance with
good laboratory practices and good manufacturing practices.

WE HAVE NOT COMPLETED THE DEVELOPMENT OF OTHER PRODUCTS AND WE MAY NOT
SUCCEED IN OBTAINING THE FDA APPROVAL NECESSARY TO SELL ANY ADDITIONAL PRODUCTS.

S-8

of a product in order to apply for regulatory approval to market the product.
ESTRASORB is our only product to have been approved for sale in the United
States. Approval outside the U.S. may take longer or may require additional
clinical trials. Our product candidate ANDROSORB has completed two Phase I human
clinical studies. Additional product candidates are in preclinical laboratory or
animal studies. Before applying for FDA approval to market any additional
product candidates, we must conduct larger-scale Phase II and III human clinical
trials that demonstrate the safety and efficacy of our products to the
satisfaction of the FDA and other regulatory authorities. These processes are
expensive and can take many years to complete, and we may not be able to
demonstrate the safety and efficacy of our products to the satisfaction of such
regulatory authorities. We may also be required to demonstrate that our proposed
products represent an improved form of treatment over existing therapies and we
may be unable to do so without conducting further clinical studies.

We may fail to obtain regulatory approval for our products on a timely
basis. Delays in obtaining regulatory approval can be extremely costly in terms
of lost sales opportunities and increased clinical trial costs. The speed with
which we complete our clinical trials and our applications for marketing
approval will depend on several factors, including the following:

o the rate of patient enrollment, which is a function of many factors,
including the size of the patient population, the proximity of patients
to clinical sites, the eligibility criteria for the study and the nature
of the protocol;

o institutional review board approval of the protocol and the informed
consent form;

o prior regulatory agency review and approval;

o analysis of data obtained from preclinical and clinical activities,
which are susceptible to varying interpretations and which
interpretations could delay, limit or prevent regulatory approval;

o changes in the policies of regulatory authorities for drug approval
during the period of product development; and

o the availability of skilled and experienced staff to conduct and monitor
clinical studies and to prepare the appropriate regulatory applications.

We have limited experience in conducting and managing the preclinical and
clinical trials necessary to obtain regulatory marketing approvals. We may not
be able to obtain the approvals necessary to conduct clinical studies. We also
face the risk that the results of our clinical trials may be inconsistent with
the results obtained in preclinical studies or that the results obtained in
later phases of clinical trials may be inconsistent with those obtained in
earlier phases. A number of companies in the specialty biopharmaceutical
industry have suffered significant setbacks in advanced clinical trials, even
after experiencing promising results in early animal and human testing. If
regulatory approval of a drug is granted, such approval is likely to limit the
indicated uses for which it may be marketed. Furthermore, even if a product
gains regulatory approval, the product and the manufacturer of the product will
be subject to continuing regulatory review. We may be restricted or prohibited
from marketing or manufacturing a product, even after obtaining product
approval, if previously unknown problems with the product or its manufacture are
subsequently discovered.

OUR SUCCESS DEPENDS ON OUR ABILITY TO MAINTAIN THE PROPRIETARY NATURE OF OUR
TECHNOLOGY.

Our success in large part depends on our ability to maintain the proprietary
nature of our technology and other trade secrets, including our proprietary drug
delivery and vaccine technologies. To do so, we must prosecute and maintain
existing patents, obtain new patents and pursue trade secret and other
intellectual property protection. We also must operate without infringing the
proprietary rights of third parties or letting third parties infringe our
rights. We currently have 51 U.S. patents and corresponding foreign patents and
patent applications covering our technologies. However, patent issues relating
to pharmaceuticals involve complex legal, scientific and factual questions. To
date, no consistent policy has emerged regarding the breadth of biotechnology
patent claims that are granted by the U.S. Patent and Trademark Office or
enforced by the federal courts. Therefore, we do not know

S-9

whether our patent applications will result in the issuance of patents, or that
any patents issued to us will provide us with any competitive advantage. We also
cannot be sure that we will develop additional proprietary products that are
patentable. Furthermore, there is a risk that others will independently develop
or duplicate similar technology or products or circumvent the patents issued to
us.

There is a risk that third parties may challenge our existing patents or
claim that we are infringing their patents or proprietary rights. We could incur
substantial costs in defending patent infringement suits or in filing suits
against others to have their patents declared invalid or claim infringement. It
is also possible that we may be required to obtain licenses from third parties
to avoid infringing third-party patents or other proprietary rights. We cannot
be sure that such third-party licenses would be available to us on acceptable
terms, if at all. If we are unable to obtain required third-party licenses, we
may be delayed in or prohibited from developing, manufacturing or selling
products requiring such licenses.

Although our patents include claims covering various features of our
products and product candidates, including composition, methods of manufacture
and use, our patents do not provide us with complete protection against the
development of competing products. For example, our patents do not prohibit
third parties from developing and selling products for estrogen therapy that
deliver estrogen through a topical emulsion, ointment or similar medium.

Some of our know-how and technology is not patentable. To protect our
proprietary rights in unpatentable intellectual property and trade secrets, we
require employees, consultants, advisors and collaborators to enter into
confidentiality agreements. These agreements may not provide meaningful
protection for our trade secrets, know-how or other proprietary information in
the event of any unauthorized use or disclosure.

HEALTH CARE INSURERS AND OTHER PAYORS MAY NOT PAY FOR OUR PRODUCTS OR MAY
IMPOSE LIMITS ON REIMBURSEMENT.

Our ability to successfully commercialize ESTRASORB and future products will
depend, in part, on the extent to which reimbursement for such products will be
available from third-party payors such as Medicare, Medicaid, health maintenance
organizations, health insurers and other public and private payors. If we
succeed in bringing future products to the market in addition to ESTRASORB, we
cannot be assured that third-party payors will pay for ESTRASORB or such future
products or establish and maintain price levels sufficient for realization of an
appropriate return on our investment in product development. For example,
ESTRASORB currently is being sold as an outpatient prescription drug. Medicare
does not cover the costs of most outpatient prescription drugs. We expect that
over time ESTRASORB will be treated the same as other estrogen therapy products
with respect to government and third-party payor reimbursement, however,
additional time is required to increase the number of payors who currently
accept our product for reimbursement. There can be no assurance that ESTRASORB
will receive similar reimbursement treatment.

Many health maintenance organizations and other third-party payors use
formularies, or lists of drugs for which coverage is provided under a health
care benefit plan, to control the costs of prescription drugs. Each payor that
maintains a drug formulary makes its own determination as to whether a new drug
will be added to the formulary and whether particular drugs in a therapeutic
class will have preferred status over other drugs in the same class. This
determination often involves an assessment of the clinical appropriateness of
the drug and, in some cases, the cost of the drug in comparison to alternative
products. There can be no assurance that ESTRASORB or any of our future products
will be added to payors' formularies, that our products will have preferred
status to alternative therapies, or that the formulary decisions will be
conducted in a timely manner. We may also decide to enter into discount or
formulary fee arrangements with payors, which could result in us receiving lower
or discounted prices for ESTRASORB or future products.

WE MAY HAVE PRODUCT LIABILITY EXPOSURE.

S-10

prior to FDA approval. Coverage is becoming increasingly expensive, however, and
we may not be able to maintain insurance at a reasonable cost. There can be no
assurance that we will be able to maintain our existing insurance coverage or
obtain coverage for the use of our other products in the future. This insurance
coverage and our resources may not be sufficient to satisfy liabilities
resulting from product liability claims. A successful claim may prevent us from
obtaining adequate product liability insurance in the future on commercially
desirable terms, if at all. Even if a claim is not successful, defending such a
claim would be time-consuming and expensive, may damage our reputation in the
marketplace, and would likely divert management's attention.

WE HAVE MADE LOANS TO CERTAIN OF OUR DIRECTORS, AND HAVE GUARANTEED A
BROKERAGE MARGIN LOAN FOR ONE OF THESE DIRECTORS, WHICH COULD HAVE A NEGATIVE
IMPACT ON OUR STOCK PRICE.

In 2002, pursuant to our 1995 Stock Option Plan, we approved the payment of
the exercise price of options by two of our directors through the delivery of
full-recourse, interest-bearing promissory notes, in the aggregate principal
amount of approximately $1.5 million, secured by a pledge of the underlying
shares. As of December 31, 2004, accrued interest receivable related to the
borrowing was $209,000. In addition, in 2002 we executed a conditional guaranty
of a brokerage margin account for a director in the amount of $500,000. Due to
heightened sensitivity in the current environment surrounding related-party
transactions, these transactions could be viewed negatively in the market and
our stock price could be negatively affected. Our corporate governance policies
have been revised and our 2005 stock incentive plan prohibits any additional
loans or guarantees to directors.

THE PRICE OF OUR COMMON STOCK HAS BEEN AND MAY CONTINUE TO BE VOLATILE; AND
IF WE ARE UNABLE TO MAINTAIN COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS, OUR
STOCK COULD BE DELISTED.

Historically, the market price of our common stock has fluctuated over a
wide range. In fiscal year 2004, our common stock traded in a range from a low
of $2.88 to a high of $6.99. Between January 1, 2005 and June 29, 2005, our
common stock traded in a range from a low of $1.13 to a high of $3.35. It is
likely that the price of our common stock will fluctuate in the future. The
market prices of securities of small-capitalization, specialty biopharmaceutical
companies, including ours, from time to time experience significant price and
volume fluctuations unrelated to the operating performance of these companies.
In particular, the market price of our common stock may fluctuate significantly
due to a variety of factors, including:

o governmental agency actions including the FDA's determination with
respect to new drug applications for new products;

o our ability to obtain financing;

o our ability to develop additional products; and

o sales of our products, particularly ESTRASORB.

In addition, the occurrence of any of the risks described in this "Risk and
Factors" section could have a material and adverse impact on the market price of
our common stock.

On June 30, 2005 the closing price of our common stock as reported on the
Nasdaq National Market was $1.32 per share. Companies listed on NASDAQ are,
among other requirements, required to maintain a minimum closing bid price of
$1.00 per share. Failure to maintain compliance with NASDAQ listing requirements
could result in the delisting of our shares from trading on the NASDAQ system,
which could have a material adverse effect on the trading price, volume and
marketability of our common stock.

OUR SUBSTANTIAL INDEBTEDNESS COULD ADVERSELY AFFECT OUR CASH FLOW AND
PREVENT US FROM FULFILLING OUR OBLIGATIONS.

As of March 31, 2005 we had $36.8 million of outstanding indebtedness. Our
substantial amount of outstanding indebtedness could have significant
consequences. For example, it:

o could increase our vulnerability to general adverse economic and
industry conditions;

o requires us to dedicate a substantial portion of our cash flow from
operations to service payments on our indebtedness, reducing the
availability of our cash flow to fund future capital expenditures,
working capital, execution of our growth strategy, research and
development costs and other general corporate requirements;

o could limit our flexibility in planning for, or reacting to, changes in
our business and the pharmaceutical industry, which may place us at a
competitive disadvantage compared with competitors that have less
indebtedness; and

S-11

o could limit our ability to obtain additional funds, even when necessary
to maintain adequate liquidity.

We may incur additional indebtedness for various reasons, which would
increase the risks associated with our substantial leverage.

RISKS RELATED TO THIS OFFERING

MANAGEMENT WILL HAVE BROAD DISCRETION AS TO THE USE OF THE PROCEEDS FROM
THIS OFFERING, AND WE MAY NOT USE THE PROCEEDS EFFECTIVELY.

We have not designated the amount of net proceeds we will use for any
particular purpose. Accordingly, our management will have broad discretion as to
the application of the net proceeds and could use them for purposes other than
those contemplated at the time of this offering. Our stockholders may not agree
with the manner in which our management chooses to allocate and spend the net
proceeds. Moreover, our management may use the net proceeds for corporate
purposes that may not increase our market value or make us profitable.

BECAUSE THE TOTAL PRICE YOU WILL PAY FOR YOUR SHARES IN THE OFFERING WILL BE
MUCH GREATER THAN THE VALUE OF OUR ASSETS AFTER SUBTRACTING OUR LIABILITIES, THE
VALUE OF YOUR INVESTMENT IN OUR COMMON STOCK WILL BE DILUTED.

If you purchase our common stock in this offering, the price you will pay
for our common stock will be much greater than the book value per share of our
outstanding common stock after the offering. In addition, the total amount of
our capital will be less than it would have been had you and all of the existing
stockholders, optionees, and warrant holders paid the same amount per share for
our common stock. Accordingly, you will suffer immediate and substantial
dilution of your investment. In the past, we have issued options and warrants to
buy our common stock at prices below the offering price. You will experience
further dilution to the extent that additional shares of our common stock are
issued upon the exercise of outstanding stock options and warrants. See
"Dilution" for a detailed calculation of the dilution that will result from this
offering.

THE ISSUANCE OF SHARES OF OUR COMMON STOCK IN CONNECTION WITH THIS OFFERING
WILL CAUSE ADDITIONAL SHARES OF COMMON STOCK TO BE ISSUABLE UPON THE CONVERSION
OF CERTAIN OUTSTANDING CONVERTIBLE NOTES OF THE COMPANY.

Assuming that we issue an aggregate of 4,000,000 shares, of our common
stock at a public offering price of $1.00 per share, an additional 474,147
shares of common stock will be issuable upon the conversion of $35.0 million
aggregate principal amount of 4.75% convertible notes that are due July 15,
2009. Accordingly, you will suffer additional dilution of your investment. See
"Dilution" for a detailed calculation of the dilution that will result from this
offering.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

We caution you that this prospectus supplement, the accompanying prospectus
and the documents incorporated by reference contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements are based on management's beliefs and assumptions and on
information currently available to management, and use words such as "expect,"
"anticipate," "intend," "plan," "believe," "estimate," "may," "could,"
"possible," "forecast," or similar words and expressions. Forward-looking
statements include but are not limited to statements regarding product sales,
future results of operations, future product development and related clinical
trials, and future research and development, including FDA approval of our
product candidates. Forward-looking statements are only predictions, and
necessarily involve risks and uncertainties and other factors that may cause the
actual results, performance or achievements of Novavax, or industry results, to
be materially different from those anticipated in or implied by the
forward-looking statements. These risks, uncertainties and other factors are
discussed in the "Risk Factors" section and elsewhere in this prospectus
supplement, the accompanying prospectus and the documents incorporated by
reference and include, among other things, the following: general economic and
business conditions; competition; unexpected changes in technologies and
technological advances; ability to obtain rights to technology; ability to
obtain and enforce patents; ability to commercialize and manufacture products;
ability to establish and maintain commercial-scale manufacturing capabilities;
ability to enter into future collaborations with industry partners; results of
clinical

S-12

studies; progress of research and development activities; business abilities and
judgment of personnel; availability of qualified personnel; changes in, or
failure to comply with, governmental regulations; ability to obtain adequate
financing in the future; and other factors referenced in this prospectus
supplement, the accompanying prospectus and the documents incorporated by
reference.

USE OF PROCEEDS

After deducting the underwriting discounts and commissions and estimated
offering expenses of this offering, we will receive net proceeds from this
offering of approximately $3,650,000.

We will retain broad discretion over the use of the net proceeds from the
sale of our common stock. We currently intend to use the net proceeds from this
offering for general corporate purposes, including but not limited to:

o our internal research and development programs, such as preclinical and
clinical testing and studies of our product candidates and the
development of new technologies; and

o general working capital.

We have not determined the amounts we plan to spend on any of the areas
listed above or the timing of these expenditures, which may vary significantly
depending on various factors such as our research and development results,
regulatory approvals, competition, marketing and sales, and the market
acceptance of any products introduced by us. As a result, our management will
have broad discretion to allocate the net proceeds from this offering. Pending
application of the net proceeds as described above, we intend to invest these
net proceeds in short-term, interest-bearing, investment-grade securities.

DILUTION

Our net tangible book value at March 31, 2005 was $24.4 million, or $0.62
per share of common stock. Net tangible book value per share represents total
tangible assets less total liabilities divided by the number of outstanding
shares of our common stock on March 31, 2005. Assuming that we issue an
aggregate of 4,000,000 shares of our common stock at a public offering price of
$1.00 per share, with estimated net proceeds to us (after assumed commissions
and expenses) of $3,650,000, our pro forma net tangible book value at March 31,
2005 would have been $28.1 million, or $0.64 per share. This represents an
immediate increase in the tangible book value of $.02 per share to our existing
stockholders and an immediate dilution of $.36 per share to new investors
purchasing common stock in this offering, as illustrated in the following table:

Public offering price per share $1.00

Net tangible book value per share as of March 31, 2005 $0.62

Increase per share attributable to new investors $0.02

Pro forma net tangible book value per share after offering $0.64

Dilution per share to new investors $0.36

The computations in the table above assume no exercise of any outstanding
stock options or warrants or conversion of convertible notes after March 31,
2005. At June 29, 2005, there were options outstanding to purchase a total of
6,046,542 shares of our common stock at a weighted average exercise price of
$4.73 per share

S-13

and warrants outstanding to purchase 70,000 shares of our common stock at a
weighted average exercise price of $6.00 per share. If any of these options or
warrants are exercised, there will be further dilution to new investors. In
addition, assuming that we issue an aggregate of 4,000,000 shares of our common
stock at a public offering price of $1.00 per share, an additional 474,147
shares of common stock shall be issuable upon the conversion of $35.0 million
aggregate principal amount of 4.75% convertible notes due July 15, 2009.

PLAN OF DISTRIBUTION

We are offering the shares of our common stock through a placement agent.
Subject to the terms and conditions contained in the placement agent agreement
dated June 30, 2005, Lane Capital Markets, LLC has agreed to act as the
placement agent for the sale of 4,000,000 shares of our common stock. The
placement agent is not purchasing or selling any shares by this prospectus
supplement or accompanying prospectus, nor are they required to arrange the
purchase or sale of any specific number or dollar amount of shares, but have
agreed to use best efforts to arrange for the sale of all of the 4,000,000
shares of our common stock. In the event that less than $4,000,000 is deposited
in the escrow account by July 1, 2005, this offering will terminate. If this
offering terminates, all funds received from investors and held by escrow agent
will be returned, without interest.

The placement agent agreement provides that the obligations of the placement
agent and the investors are subject to certain conditions precedent, including
the absence of any material adverse change in our business and the receipt of
certain opinions, letters and certificates from our counsel, our independent
auditors and us.

Confirmations and definitive prospectuses will be distributed to all
investors who agree to purchase shares of the common stock, informing investors
of the closing date as to such shares. We currently anticipate that closing of
the sale of 4,000,000 shares of common stock will take place on or about July
1, 2005. Investors will also be informed of the date and manner in which they
must transmit the purchase price for their shares.

On the scheduled closing date, the following will occur:

o we will receive funds in the amount of the aggregate purchase price; and

o Lane Capital Markets, LLC will receive the placement agent's fee in
accordance with the terms of the placement agent agreement, and
reimbursement of expenses not to exceed $20,000.

We will pay the placement agent an aggregate commission equal to 5% of the
gross proceeds of the sale of shares of common stock in the offering. In no
event will the total amount of compensation paid to the placement agents and
other securities brokers and dealers upon completion of this offering exceed 5%
of the maximum gross proceeds of the offering. The estimated offering expenses
payable by us, in addition to the placement agents' fee, are approximately
$150,000, which includes legal, accounting and printing costs and various other
fees associated with registering and listing the shares of common stock. After
deducting certain fees due to the placement agents and our estimated offering
expenses, we expect the net proceeds from this offering to be approximately
$3,650,000.

We have agreed to indemnify the placement agent against certain liabilities,
including liabilities under the Securities Act of 1933, as amended. We have also
agreed to contribute to payments the placement agent may be required to make in
respect of such liabilities.

The placement agent agreement with Lane Capital Markets, LLC is included as
an exhibit to our Current Report on Form 8-K that will be filed with the
Securities and Exchange Commission in connection with the consummation of this
offering.

The transfer agent for our common stock is EquiServe.

Our common stock is traded on the Nasdaq National Market under the symbol
"NVAX."

S-14

LEGAL MATTERS

Certain legal matters with respect to the shares of common stock offered
hereby have been passed upon by Ropes & Gray LLP in New York, New York. McCarter
& English, LLP in Newark, New Jersey is acting as counsel for the placement
agent.

S-15

THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. WE MAY
NOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER
TO SELL THESE SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY THESE
SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.

PROSPECTUS

Subject to Completion, Dated November 12, 2003

---------------------

$50,000,000

NOVAVAX, INC.
COMMON STOCK

---------------------

We may sell from time to time shares of our common stock, par value $.01
per share, in one or more offerings with a maximum aggregate offering price of
$50,000,000. This means:

- we will provide a prospectus supplement each time we issue common stock;
and

- the prospectus supplement will inform you about the specific terms of
that offering and may also add, update or modify information contained
in this document.

---------------------

Our common stock is traded on the Nasdaq National Market under the
symbol NVAX. On August 8, 2003, the closing price of our common stock as
reported on the Nasdaq National Market was $5.66 per share.

---------------------

Our principal offices are located at 8320 Guilford Road, Columbia,
Maryland 21046. Our telephone number is (301) 854-3900.

---------------------

INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK.
SEE "RISK FACTORS" BEGINNING ON PAGE 6.

---------------------

Neither the Securities and Exchange Commission nor any other regulatory body has
approved or disapproved of these securities or passed upon the adequacy or
accuracy of this prospectus. Any representation to the contrary is a criminal
offense.

THE DATE OF THIS PROSPECTUS IS _________, 2003.

TABLE OF CONTENTS

PAGE
----

Prospectus Summary........................................................................................ 3
Risk Factors.............................................................................................. 6
About this Prospectus..................................................................................... 14
Special Note Regarding Forward-Looking Statements......................................................... 15
Use of Proceeds........................................................................................... 16
Plan of Distribution...................................................................................... 17
Description of Our Capital Stock.......................................................................... 20
Dividend Policy........................................................................................... 22
Legal Matters............................................................................................. 22
Experts................................................................................................... 22
Where You Can Find More Information....................................................................... 22
Incorporation of Certain Information by Reference......................................................... 23

---------------------

You should rely only on the information contained in this prospectus and
in any prospectus supplement. We have not authorized anyone to provide you with
information different from that contained in this prospectus or any prospectus
supplement. We are offering to sell our common stock, and seeking offers to buy,
only in jurisdictions where offers and sales are permitted. The information
contained in this prospectus is accurate only as of the date of this prospectus,
regardless of the time of delivery of this prospectus or any sale of our common
stock.

---------------------

In this prospectus, the "Company," "we," "us" and "our" refer to
Novavax, Inc., together with its subsidiaries, unless the context otherwise
requires.

-2-

PROSPECTUS SUMMARY

This summary highlights selected information contained elsewhere or
incorporated by reference in this prospectus, and may not contain all of the
information that is important to you. For a more complete understanding of this
offering, you should read this entire document carefully before deciding to
invest in our common stock, including the "Risk Factors" section below, and
those additional documents to which we refer you. See "Where You Can Find More
Information" on page 22.

OUR BUSINESS

Novavax is a fully-integrated specialty pharmaceutical company focused
on the research, development and commercialization of products utilizing our
proprietary drug delivery and vaccine technologies for large and growing
markets, concentrating on the areas of women's health and infectious diseases.
Our lead product candidate, ESTRASORB(TM), is the first topical emulsion for
estrogen replacement therapy for which a New Drug Application has been accepted
for review by the Food and Drug Administration. The NDA for ESTRASORB was
submitted in June 2001 and was accepted for review in August 2001. In April
2002, we were informed by the FDA that the agency had completed its review of
the NDA for ESTRASORB. At that time, the agency did not raise any issues
regarding the efficacy or safety of ESTRASORB, but did request additional
information with respect to the Chemistry, Manufacturing and Controls section of
the filing. We determined that the most advantageous approach to resolving the
outstanding CMC questions was to voluntarily withdraw the NDA and resubmit it
once all of the responses to the CMC questions had been prepared. In September
2002, we re-submitted the NDA, which was accepted for review by the FDA in
November 2002. In June 2003, the agency informed us that it would need
additional time for a full review of our Estradiol Partner Transfer Study Report
submitted in May of this year. Under the Prescription Drug User Fee Act the
statutory minimum extension time is 90 days, which thus results in a new goal
date for a decision on the approvability of ESTRASORB of no later than October
10, 2003. We are seeking FDA approval of ESTRASORB for the reduction of hot
flushes in menopausal women and, if approved, we believe ESTRASORB will be
competitively positioned to address the estimated $1.8 billion estrogen
replacement therapy market in the United States.

Our micellar nanoparticle technology involves the use of our patented
oil and water emulsions that we believe can be used as vehicles for the topical
delivery of a wide variety of drugs and other therapeutic products, including
hormones. We believe that our technology represents the first time that ethanol
soluble hormones, such as estrogen and testosterone, have been encapsulated and
delivered topically. In addition to ESTRASORB, our product candidates using
these technologies include ANDROSORB(TM), a topical testosterone emulsion that
has completed two Phase I clinical trials; TESTESTRASORB(TM), a topical estrogen
and testosterone emulsion; PROGESTSORB(TM) NE, a topical progestin emulsion; and
PROESTRASORB(TM), a topical estrogen and progestin emulsion. Other drug delivery
technologies, such as our Novasome(R) and Sterisome(R) technologies, are being
utilized to develop other products. Novasomes are used as adjuvants to enhance
vaccine effectiveness. Sterisomes are being used for, among other things,
subcutaneous injections that can deliver long-acting drug effects. We also
conduct research and development on preventative vaccines and proteins for a
variety of infectious diseases and immunotherapies.

Over the past three years we have entered into a co-promotion agreement
with King Pharmaceuticals, Inc. for the promotion and marketing of ESTRASORB and
ANDROSORB within the United States and Puerto Rico, and we have licensed to King
the right to sell these products outside the United States. Our relationship
with King has the potential to provide us with broader women's health market
coverage for ESTRASORB and ANDROSORB. Under the terms of our co-promotion
agreement with King, we will record all of the product sales, returns and
allowances, and cost of sales for ESTRASORB and ANDROSORB in the United States
and Puerto Rico. The resultant gross margin will be shared equally with King and
the payment to King will be recorded as a selling and marketing expense on our
statement of operations. In addition, following product approval by the FDA,
both parties will share equally in approved marketing expenses for the products.
All direct marketing expenses will be recorded by us, for which King will
reimburse us fifty percent. We received licensing fees of $3.0 million and
milestone payments totaling $5.0 million from King upon the submission to the
FDA and acceptance for review of the ESTRASORB NDA. We have also received from
King $20.0 million in December 2000, $10.0 million in September 2001 and $10.0
million in June 2002, in the form of convertible note financings.

-3-

We currently market, sell and distribute a line of prescription
pharmaceuticals through our 64 person sales force that has extensive experience
selling to obstetricians, gynecologists, managed care organizations, wholesalers
and retail pharmacies throughout the United States. In 2002, these products
generated revenues of $12.8 million. If we receive marketing approval from the
FDA, we expect to sell ESTRASORB through both our sales force and King's sales
force. We intend to manufacture ESTRASORB for commercial sale in our dedicated,
state-of-the-art, 24,000 square foot facility in Philadelphia, Pennsylvania,
which was substantially completed in December 2002.

Our principal executive offices are located at 8320 Guilford Road,
Columbia, MD 21046. Our telephone number is (301) 854-3900. We are incorporated
under the laws of the State of Delaware.

-4-

SUMMARY CONSOLIDATED FINANCIAL DATA

The historical consolidated financial data presented below as of and for
each of the periods ended December 31, 2002, 2001 and 2000 were derived from our
audited consolidated financial statements. The summary consolidated financial
data is only a summary and should be read in conjunction with our consolidated
financial statements and related notes that we incorporate by reference in this
prospectus. For copies of the financial information we incorporate by reference,
see "Where You Can Find More Information" on page 22.

Information as of June 30, 2003 and for the six months ended June 30,
2003 and 2002 has been derived from our consolidated financial statements, which
are unaudited but which in the opinion of management have been prepared on the
same basis as the audited consolidated financial statements and include all
adjustments necessary (consisting of normal recurring adjustments) for a fair
presentation of the results for such periods. The results of operations for the
quarter ended June 30, 2003 are not necessarily indicative of the results to be
expected for the entire year ending December 31, 2003 or any future period.

(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE INFORMATION)
-----------------------------------------------------------------------
for the six months ended for the years ended
June 30, December 31,
---------------------- -----------------------------------------------------------------
2003 2002 2002 2001 2000 1999 1998
---- ---- ---- ---- ---- ---- ----
(unaudited) (unaudited) (restated)

STATEMENT OF OPERATIONS DATA:

Revenues.......................$ 3,469 $10,177 $15,005 $24,066 $ 2,475 $ 1,181 $ 681
Loss from operations (10,033) (10,990) (21,558) (9,255) (12,742) (4,566) (5,152)
Net loss ....................... (10,830) (11,500) (22,697) (9,745) (12,191) (4,506) (4,817)
Per share information:
Net loss per share.............$ (0.38) $ (0.48) $ (0.93) $ (0.43) $ (0.64) $ (0.31) $(0.39)
Weighted average number of
shares outstanding........... 28,489,651 24,209,198 24,433,868 22,670,274 19,015,719 14,511,081 12,428,426

As of June 30, As of December 31,
---------------------- ----------------------------------------------------------
2003 2002 2002 2001 2000 1999 1998
---- ---- ---- ---- ---- ---- ----
(unaudited) (unaudited) (restated)

BALANCE SHEET DATA:

Total current assets...........$ 12,837 $21,100 $ 6,242 $25,027 $ 17,036 $ 1,143 $1,207
Working capital 8,646 13,326 378 18,030 12,331 (480) 349
Total assets ....................63,908 69,387 57,505 67,115 56,529 4,463 3,819
Convertible debt.................40,000 40,000 40,000 30,000 20,000 -- --
Stockholders' equity.............16,122 19,113 8,073 27,493 31,824 2,840 2,961

-5-

RISK FACTORS

You should carefully read the following risk factors in addition to the
remainder of this prospectus before purchasing any shares of our common stock.
Some of the following risks relate principally to our business and the industry
in which we operate. Other risks relate principally to the securities market and
ownership of our common stock. If any of the following risks occur, our
business, financial condition and/or operating results could be adversely
affected. In that case, the trading price of our common stock could decline, and
you could lose all or part of your investment.

OUR SUCCESS IS HEAVILY DEPENDENT ON FDA APPROVAL AND MARKET ACCEPTANCE
OF ESTRASORB.

Our New Drug Application for ESTRASORB was accepted for review by the
FDA in November 2002. There is no guarantee that the FDA will approve our
application and allow us to begin selling ESTRASORB in the United States. If we
do not receive FDA approval of our application, our inability to sell ESTRASORB
in the United States would have a significant negative effect on our business
and results of operations. Even if ESTRASORB is approved by the FDA, there is no
guarantee that we and King Pharmaceuticals, Inc., our marketing partner for
ESTRASORB, will be able to successfully commercialize ESTRASORB. Many factors
could negatively affect our ability to successfully commercialize ESTRASORB,
including:

- a failure or delay in ESTRASORB gaining a meaningful share of the
estrogen replacement therapy market, which currently is dominated by
Premarin(R), an oral estrogen tablet sold by Wyeth, and estrogen patches
sold by several companies including Novartis Pharma AG, Berlex
Laboratories, Inc. and Forest Pharmaceuticals, Inc.;

- our inability to effectively promote and sell ESTRASORB with King in the
United States, or King's inability to do so in the rest of the world;

- delays in the manufacture of ESTRASORB in commercial quantities; and

- the inability to obtain coverage and favorable reimbursement rates for
ESTRASORB from insurers and other third party payors.

WE WILL FACE SUBSTANTIAL COMPETITION IN CONNECTION WITH THE SALE OF
ESTRASORB AND OUR OTHER PRODUCT CANDIDATES.

We compete with numerous other companies worldwide that have developed
or are developing products that compete or may compete with our product
candidates. These competitors include both large and small pharmaceutical
companies, biotechnology firms, universities and other research institutions. We
may not succeed in developing technologies and products that are more effective
than those being developed by our competitors.

Many large companies currently produce and sell estrogen products for
clinical indications identical to those that we seek for ESTRASORB. In the oral
product segment of the estrogen replacement therapy market, which accounts for
approximately 74% of the market according to 2002 IMS Health Incorporated data,
Wyeth commits significant resources to the sale and marketing of its product,
Premarin(R), in order to maintain its market leadership position.
Warner-Chillcot also competes in the branded oral product segment with its
product, Estrace(R). In addition, ESTRASORB will compete with products produced
and sold by generic manufacturers in the oral product segment of the market,
such as Watson Pharmaceutical, Inc.'s generic product, Estropipate(R). In the
patch segment of the market, which according to IMS Health accounts for
approximately 15% of the estrogen replacement therapy market, several companies
market transdermal estrogen patches with which ESTRASORB will compete, if
approved. For example, Novartis Pharma AG currently markets and sells its
Vivelle(R) and Estraderm(R) patches and Berlex Laboratories, Inc. and Forest
Pharmaceuticals Inc. co-promote the Climara(R) transdermal patch. Several
companies also currently market ethanol-based estrogen gels and ointments
outside the United States. For example, Schering Canada sells its estrogen gel,
Estrogel(R), in Canada. These and other products sold by our competitors have
all been approved for sale and have achieved some degree of market penetration.
If ESTRASORB is approved for sale in the Untied States, it will compete for
market share with these products and we cannot guarantee that, together with
King, we will be able to effectively promote ESTRASORB against these competitive
products. In order to

-6-

effectively compete, we may make substantial investments in sales and marketing.
Many of these products are sold by companies with greater resources than we have
and there is no assurance that we will be successful in gaining significant
market share for ESTRASORB or in earning a return on that investment.

Our technologies and products may be rendered obsolete or noncompetitive
as a result of products introduced by competitors. Most of our competitors have
substantially greater financial and technical resources, production and
marketing capabilities, and related experience than we do. The greater
resources, capabilities and experience of our competitors may enable them to
develop, manufacture and market their products more successfully and at a lower
cost than we can. In addition, many of our competitors have significantly
greater experience than we do in conducting preclinical testing and clinical
trials of human pharmaceuticals and obtaining regulatory approvals to market
such products. Accordingly, our competitors may succeed in obtaining FDA
approval for products more rapidly than we will, which may give them an
advantage over us in achieving market acceptance of their products.

WE WOULD NEED ADDITIONAL CAPITAL TO GROW AND OPERATE OUR BUSINESS IN THE
EVENT WE WERE UNABLE TO RAISE CAPITAL IN THIS OFFERING, AND WE ARE UNCERTAIN
ABOUT OBTAINING FUTURE FINANCING.

We estimate that our existing cash resources will be sufficient to
finance our operations at current and projected levels of development and
general corporate activity for the next 5 to 7 months. We cannot be certain that
we will be able to generate revenues from product sales in the near term or at
all sufficient to fund our operations. If w were unable to raise capital in this
offering, we would require additional funds to continue our research and
development, commence future preclinical and clinical trials, seek regulatory
approvals, establish commercial-scale manufacturing capabilities, and market our
products. We may seek additional funds through public or private equity or debt
financings, collaborative arrangements with pharmaceutical companies and other
sources. We cannot be certain that adequate additional funding will be available
to us on acceptable terms, if at all. If we cannot raise the additional funds we
may need to continue our current and anticipated operations, we may be required
to delay significantly, reduce the scope of, or eliminate one or more of, our
research or development programs. If that is the case, we will seek other
alternatives to avoid insolvency, including arrangements with collaborative
partners or others that may require us to relinquish rights to certain of our
technologies, product candidates or products.

WE HAVE A HISTORY OF LOSSES AND OUR FUTURE PROFITABILITY IS UNCERTAIN.

Our expenses have exceeded our revenues since our formation in 1987, and
our accumulated deficit at June 30, 2003 was $98.4 million. Our revenues for the
last three years were $15.0 million in 2002, $24.0 million in 2001 and $2.5
million in 2000. For the six months ended June 30, 2003 and 2002, our revenues
were $3.5 million and $10.2 million, respectively. Sales of products that we
acquired as a result of our acquisition of Fielding Pharmaceutical Company in
2000 have generated modest revenues, but based on our current business plan
these revenues will not be sufficient to offset our expenses in the future. We
cannot be certain when or if we will generate substantial revenues from the sale
of ESTRASORB. We have received a very limited amount of product-related revenue
from research contracts, licenses and agreements to provide vaccine products,
services and adjuvant technologies. We cannot be certain that we will be
successful in entering into strategic alliances or collaborative arrangements
with other companies that will result in other significant revenues to offset
our expenses. Our net losses for the last three years were $22.7 million in
2002, $9.7 million in 2001 and $12.1 million in 2000, while they were $10.8
million and $11.5 million for the six months ended June 30, 2003 and 2002,
respectively. Our losses have resulted from research and development expenses,
pre-launch sales and marketing expenses in the anticipation of FDA approval for
ESTRASORB, protection of our intellectual property, and other general operating
expenses. Our annual losses may increase depending on the timing of the FDA
approval and launch of ESTRASORB as we expand our manufacturing capacity, sales
and marketing capabilities and conduct additional and larger clinical trials for
other product candidates. Therefore, we expect our cumulative operating loss to
increase until such time, if ever, as product sales, licensing fees and royalty
payments generate sufficient revenue to fund our continuing operations. We
cannot predict when, if ever, we might achieve profitability and cannot be
certain that we will be able to sustain profitability, if achieved.

We intend to allocate a significant portion of our sales force's time to
the product launch of ESTRASORB, if and when it is approved by the FDA.
Accordingly, the sales of our other women's health products could be adversely
affected by the efforts we allocate to the ESTRASORB product launch. The costs
of maintaining our own

-7-

sales force to market our current products and ESTRASORB, if approved, may in
the future exceed product revenues. If we continue to market ESTRASORB or future
products directly, significant additional expenditures and management resources
may be required to increase the size of our internal sales force.

OUR SALES AND MARKETING PLAN FOR ESTRASORB DEPENDS IN LARGE PART ON THE
SUCCESS OF OUR RELATIONSHIP WITH KING.

We have entered into a co-promotion agreement with King for the
marketing and promotion of ESTRASORB in the United States using our sales and
marketing personnel and King's sales and marketing personnel. We have also
granted King exclusive rights to promote, market and distribute ESTRASORB
outside the United States. In return, we received certain milestone payments and
the agreement to pay potential future milestone payments and licensing fees and
royalties on future sales. While our agreements with King give us some limited
protections with respect to King's marketing and sales efforts and, we believe,
create financial incentives for King consistent with our own, we cannot control
the amount and timing of marketing efforts that King devotes to ESTRASORB or
make any assurances that our and King's co-promotion of ESTRASORB in the United
States and King's marketing of ESTRASORB in the rest of the world will be
successful.

Our success in marketing other potential future products will also
depend in large part on our relationship with King. Our co-promotion agreement
with King also provides for co-promotion in the United States with King of our
product candidate ANDROSORB(TM). If this product is approved for marketing by
the FDA, King has an exclusive worldwide license, except in the United States,
to market this future product. Under our co-promotion agreement, King has the
right to co-promote certain future hormone replacement therapy products in the
field of women's health. In the future, we might enter into other licensing or
co-promotion arrangements with King or other third parties for the marketing and
sale of other future products. Any revenues we receive from sales of ANDROSORB
and other future products will depend in large part on the terms of these
agreements and the efforts of King and any other third-party marketing partners.

OUR AGREEMENTS WITH KING REDUCE THE LIKELIHOOD THAT WE COULD BE ACQUIRED
BY ANOTHER COMPANY.

Our co-promotion agreement and license agreement with King for the
marketing of ESTRASORB and ANDROSORB contain several provisions that would take
effect upon a change of control of the Company. One provision allows King
several options in the event of a change in control of Novavax including (i)
terminating our right to co-promote King products, (ii) terminating our rights
to promote ESTRASORB and ANDROSORB and certain other hormone therapies for
women, or (iii) requiring Novavax to assign and transfer to King all related
rights of ownership for ESTRASORB and ANDROSORB and certain other hormone
replacement therapies for women and license to King on an exclusive and
perpetual basis all intellectual property rights and know-how. If King chooses
to exercise its rights under either clause (ii) or (iii) above, King will pay us
royalties on net sales of the products. In addition, King will pay us for the
cost of manufacturing, plus a markup consistent with the terms of the license
agreement for the handling costs. King could also require that we redeem the
outstanding promissory notes, currently in the amount of $40.0 million, at 101%
of the outstanding principal and accrued interest. These provisions may have the
effect of making us less attractive as an acquisition candidate.

WE NEED ADDITIONAL MANUFACTURING CAPABILITY TO COMMERCIALIZE OUR
PRODUCTS.

We do not have any experience with the large capacity manufacturing
required for commercial sale of a product. Although we have had the ability to
produce the limited quantities of products needed to support our current
research and development program and clinical trials (including utilizing
contract manufacturing organizations), we will need more production capacity for
larger, later-stage clinical studies and commercial sales. Our potential
products may be too difficult or costly to manufacture on a large scale, to
develop into commercially viable products or to market.

We have validated our manufacturing methods for ESTRASORB, which has
been produced in 100-kilo size batches. Such validation is required under FDA
guidelines, and we have received preliminary FDA approval of these methods. We
currently manufacture ESTRASORB at a facility of Cardinal Health, Inc. in
Philadelphia, Pennsylvania. In February 2002, we entered into an agreement with
Cardinal Health to lease approximately 24,000 square feet of space within their
facility. Under the terms of this agreement, Cardinal Health will also provide

-8-

packaging services for the product we manufacture in their facility. We have
substantially completed the build out of the facility to meet our requirements
and have installed manufacturing equipment at this facility with the capacity
required for commercial production of ESTRASORB. Now that this new equipment is
installed, we need to validate that the ESTRASORB made using this new equipment
is identical to that used in our clinical trials. If we are unable to make
ESTRASORB on a commercial scale or are delayed in validating the product
manufactured with our new equipment, the commercialization of ESTRASORB would be
delayed.

In the near term, we will be manufacturing ESTRASORB only in the
Philadelphia facility. If ESTRASORB is approved by the FDA, we plan to qualify
at least one additional site for the manufacture of ESTRASORB. If we are unable
to utilize the Philadelphia facility to manufacture ESTRASORB prior to our
qualification of a second site, however, we would not have immediate access to
ESTRASORB and would be required to reestablish our validation process at a
different facility that would cause us to lose sales of ESTRASORB and would
adversely affect our business.

We currently utilize third party contract manufacturers to manufacture
our other products. Any contract manufacturer's facility that we may use,
including the Cardinal Health facility, must adhere to the FDA's regulations on
current good manufacturing practices, which are enforced by the FDA through its
facilities inspection program. These facilities are subject to periodic
inspection by the FDA. The manufacture of products at these facilities will be
subject to strict quality control testing and record-keeping requirements. We
may not be able to enter into alternative manufacturing arrangements at
commercially acceptable rates, if at all. Moreover, the manufacturers we use may
not provide sufficient quantities of product to meet our specifications or our
delivery, cost and other requirements.

If we decide to manufacture our own products, we will need to acquire
additional manufacturing facilities and to improve our manufacturing technology.
Establishing additional manufacturing facilities will require us to spend
substantial funds, hire and retain a significant number of additional personnel
and comply with extensive regulations applicable to such facilities here and
abroad, including the current good laboratory practices and good manufacturing
practices required by the FDA. If we elect to or need to manufacture our own
products, we risk the possibility that we may not be able to do so in a timely
fashion at acceptable quality and prices or in compliance with good laboratory
practices and good manufacturing practices.

WE HAVE NOT COMPLETED THE DEVELOPMENT OF MANY OF OUR PRODUCTS AND WE MAY
NOT SUCCEED IN OBTAINING THE FDA APPROVAL NECESSARY TO SELL ANY ADDITIONAL
PRODUCTS.

The development, manufacture and marketing of our pharmaceutical
products are subject to government regulation in the United States and other
countries. In the United States and most foreign countries, we must complete
rigorous preclinical testing and extensive human clinical trials that
demonstrate the safety and efficacy of a product in order to apply for
regulatory approval to market the product. Only a few of our products have been
approved for sale and our application to sell ESTRASORB in the United States is
currently being reviewed by the FDA. Our product candidate, ANDROSORB, has
completed two Phase I human clinical studies. Our other product candidates are
in preclinical laboratory or animal studies. Before applying for FDA approval to
market any additional product candidates, we must conduct larger-scale Phase II
and III human clinical trials that demonstrate the safety and efficacy of our
products to the satisfaction of the FDA or other regulatory authorities. These
processes are expensive and can take many years to complete. We may not be able
to demonstrate the safety and efficacy of our products to the satisfaction of
the FDA or other regulatory authorities. We may also be required to demonstrate
that our proposed products represent an improved form of treatment over existing
therapies and we may be unable to do so without conducting further clinical
studies.

- the rate of patient enrollment, which is a function of many factors,
including the size of the patient population, the proximity of patients
to clinical sites, the eligibility criteria for the study and the nature
of the protocol;

-9-

- institutional review board approval of the protocol and the informed
consent form;

- prior regulatory agency review and approval;

- analysis of data obtained from preclinical and clinical activities that
are susceptible to varying interpretations, which interpretations could
delay, limit or prevent regulatory approval;

- changes in the policies of regulatory authorities for drug approval
during the period of product development; and

- the availability of skilled and experienced staff to conduct and monitor
clinical studies and to prepare the appropriate regulatory applications.

We have limited experience in conducting and managing the preclinical
and clinical trials necessary to obtain regulatory marketing approvals. We may
not be able to obtain the approvals necessary to conduct clinical studies. Also,
the results of our clinical trials may not be consistent with the results
obtained in preclinical studies or the results obtained in later phases of
clinical trials may not be consistent with those obtained in earlier phases. A
number of companies in the specialty pharmaceutical industry have suffered
significant setbacks in advanced clinical trials, even after experiencing
promising results in early animal and human testing. If regulatory approval of a
drug is granted, such approval is likely to limit the indicated uses for which
it may be marketed. Furthermore, even if a product of ours gains regulatory
approval, the product and the manufacturer of the product will be subject to
continuing regulatory review. We may be restricted or prohibited from marketing
or manufacturing a product, even after obtaining product approval, if previously
unknown problems with the product or its manufacture are subsequently
discovered.

OUR SUCCESS DEPENDS ON OUR ABILITY TO MAINTAIN THE PROPRIETARY NATURE OF
OUR TECHNOLOGY.

Our success will, in large part, depend on our ability to maintain the
proprietary nature of our technology and other trade secrets. To do so, we must
prosecute and maintain existing patents, obtain new patents and pursue trade
secret protection. We also must operate without infringing the proprietary
rights of third parties or letting third parties infringe our rights. We
currently have 55 U.S. patents and approximately 150 foreign patents and patent
applications covering our technologies. We recently filed eight new patent
applications in the US and worldwide directed towards innovative discoveries
made in the field of human Papillomavirus virus-like particles. However, patent
issues relating to pharmaceuticals involve complex legal, scientific and factual
questions. To date, no consistent policy has emerged regarding the breadth of
biotechnology patent claims that are granted by the United States Patent and
Trademark Office or enforced by the federal courts. Therefore, we do not know
whether our applications will result in the issuance of patents, or that any
patents issued to us will provide us with any competitive advantage. We also
cannot be sure that we will develop additional proprietary products that are
patentable. Furthermore, there is a risk that others will independently develop
or duplicate similar technology or products or circumvent the patents issued to
us.

There is a risk that third parties may challenge our existing patents or
may claim that we are infringing their patents or proprietary rights. We could
incur substantial costs in defending patent infringement suits or in filing
suits against others to have their patents declared invalid or claim
infringement. It is also possible that we may be required to obtain licenses
from third parties to avoid infringing third-party patents or other proprietary
rights. We cannot be sure that such third-party licenses would be available to
us on acceptable terms, if at all. If we are unable to obtain required
third-party licenses, we may be delayed in or prohibited from developing,
manufacturing or selling products requiring such licenses.

Although our patents include claims covering various features of our
product candidates, including composition, methods of manufacture and use, our
patents do not provide us with complete protection against the development of
competing products. For example, our patents do not prohibit third parties from
developing and selling products for estrogen replacement therapy that deliver
estrogen through a topical emulsion, ointment or similar medium.

-10-

HEALTH CARE INSURERS AND OTHER PAYORS MAY NOT PAY FOR OUR PRODUCTS OR
MAY IMPOSE LIMITS ON REIMBURSEMENT.

Our ability to commercialize ESTRASORB and our future products will
depend, in part, on the extent to which reimbursement for such products will be
available from third-party payors, such as Medicare, Medicaid, health
maintenance organizations, health insurers and other public and private payors.
If we succeed in bringing ESTRASORB or other products in the future to market,
we cannot be assured that third-party payors will pay for ESTRASORB or will
establish and maintain price levels sufficient for realization of an appropriate
return on our investment in product development. For example, ESTRASORB, if
approved for commercial sale in the United States, would be sold as an
outpatient prescription drug. Medicare does not cover the costs of most
outpatient prescription drugs. We expect that ESTRASORB will be treated the same
as other estrogen replacement therapy products with respect to government and
third-party payor reimbursement. However, we cannot be assured that ESTRASORB
will receive similar reimbursement treatment.

Many health maintenance organizations and other third-party payors use
formularies, or lists of drugs for which coverage is provided under a health
care benefit plan, to control the costs of prescription drugs. Each payor that
maintains a drug formulary makes its own determination as to whether a new drug
will be added to the formulary and whether particular drugs in a therapeutic
class will have preferred status over other drugs in the same class. This
determination often involves an assessment of the clinical appropriateness of
the drug and sometimes the cost of the drug in comparison to alternative
products. We cannot be assured that ESTRASORB or any of our future products will
be added to payors' formularies, that our products will have preferred status to
alternative therapies, or that the formulary decisions will be conducted in a
timely manner. We may also decide to enter into discount or formulary fee
arrangements with payors, which could result in us receiving lower or discounted
prices for ESTRASORB or future products.

WE MAY HAVE PRODUCT LIABILITY EXPOSURE.

The administration of drugs to humans, whether in clinical trials or
after marketing clearances are obtained, can result in product liability claims.
We maintain product liability insurance coverage in the total amount of $18.0
million for claims arising from the use of our currently marketed products and
products in clinical trials prior to FDA approval. Coverage is becoming
increasingly expensive, however, and we may not be able to maintain insurance at
a reasonable cost. We cannot be assured that we will be able to maintain our
existing insurance coverage or obtain coverage for the use of our other products
in the future. This insurance coverage and our resources may not be sufficient
to satisfy liabilities resulting from product liability claims. A successful
claim may prevent us from obtaining adequate product liability insurance in the
future on commercially desirable terms, if at all. Even if a claim is not
successful, defending such a claim may be time-consuming and expensive and may
damage our reputation in the marketplace.

WE HAVE MADE LOANS TO CERTAIN OF OUR DIRECTORS, AND HAVE GUARANTEED A
BROKERAGE MARGIN LOAN FOR ONE OF THESE DIRECTORS THAT COULD HAVE A NEGATIVE
IMPACT ON OUR STOCK PRICE.

In 2002, pursuant to our Stock Option Plan, we approved the payment of
the exercise price of options by two directors through the delivery of full
recourse interest bearing promissory notes, in the aggregate amount of
approximately $1.5 million, secured by a pledge of the underlying shares. In
addition, in 2002 we executed a conditional guaranty of a brokerage margin
account for a director in the amount of $500,000. Due to heightened sensitivity
in the current environment surrounding related party transactions, these
transactions could be viewed negatively in the market and our stock price could
be negatively affected.

-11-

THE PRICE OF OUR COMMON STOCK HAS BEEN, AND MAY CONTINUE TO BE,
VOLATILE.

Historically, the market price of our common stock has fluctuated over a
wide range. In fiscal 2002, our common stock traded in a range from a low of
$1.59 to a high of $14.00. In fiscal 2003, our common stock has traded in a
range from a low of $2.52 to a high of $6.87 as of August 8, 2003. It is likely
that the price of our common stock will fluctuate in the future. The market
prices of securities of small capitalization specialty pharmaceutical companies,
including ours, from time to time experience significant price and volume
fluctuations unrelated to the operating performance of particular companies. In
particular, over the next year, the market price of our common stock may
fluctuate significantly due to a variety of factors, including:

- governmental agency actions, including the FDA's determination with
respect to our pending NDA for ESTRASORB;

- our ability to obtain financing; and

- sales of our products, particularly ESTRASORB, if it is approved for
sale.

In addition, the occurrence of any of the risks described in this "Risk Factors"
section could have a dramatic and adverse impact on the market price of our
common stock.

OUR SUBSTANTIAL DEBT COULD ADVERSELY AFFECT OUR CASH FLOW AND PREVENT US
FROM FULFILLING OUR OBLIGATIONS.

We currently have $41.6 million of outstanding debt. Our substantial
amount of debt could have important consequences to you. For example, it:

- could increase our vulnerability to general adverse economic and
industry conditions;

- will require us to dedicate a substantial portion of our cash flow from
operations to service payments on our debt, reducing the availability of
our cash flow to fund future capital expenditures, working capital,
execution of our growth strategy, research and development costs and
other general corporate requirements;

- could limit our flexibility in planning for, or reacting to, changes in
our business and the pharmaceutical industry, which may place us at a
competitive disadvantage compared with competitors that have less debt;
and

- could limit our ability to borrow additional funds, even when necessary
to maintain adequate liquidity.

We may incur additional debt for various reasons, which, if over a
certain amount, must be approved by King. Any such additional debt could be
senior to the common stock being offered in this offering and would increase the
risks associated with our substantial leverage.

OUR INABILITY TO RECRUIT AND RETAIN MEMBERS OF OUR MANAGEMENT TEAM AND
KEY PERSONNEL COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS.

Our future success will depend in part on our ability to attract and
retain highly skilled employees, particularly those in management, sales,
regulatory, manufacturing and technical positions. The loss of services of
members of our management team could adversely affect our business and impede or
delay achievement of our corporate mission. Furthermore, recruiting and
retaining qualified scientific and other key employees will be critical to our
success, and competition for such employees in our targeted industry and in our
geographic regions is intense. In addition, many of the companies with which we
compete for highly qualified personnel have greater financial and other
resources than we do. We may be unable to attract and retain key employees on
acceptable terms given the level and nature of such competition.

-12-

ANTI-TAKEOVER PROVISIONS COULD MAKE A THIRD-PARTY ACQUISITION OF US MORE
DIFFICULT.

In 2002, we adopted a Shareholder Rights Plan that provided for the
issuance of rights to purchase shares of Series D Junior Participating Preferred
Stock of the Company. Under the plan, we distributed one preferred share
purchase right for each outstanding share of common stock. Each purchase right
entitles the holder to purchase from the Company one one-thousandth (1/1000th)
of a preferred share at a price of $40 per one one-thousandth (1/1,000th) of a
share, subject to adjustment. The rights become exercisable, with certain
exceptions, ten business days after any party, without prior approval of our
Board of Directors, acquires or announces an offer to acquire beneficial
ownership of 15% or more of the Company's common stock. In the event that any
party acquires 15% or more of the Company's common stock, the Company enters
into a merger or other business combination, or if a substantial portion of the
Company's assets is sold after the time that the rights become exercisable, the
rights provide that the holder will receive, upon exercise, shares of the common
stock of the surviving or acquiring company, as applicable, having a market
value of twice the exercise price of the right. The Shareholder Rights Plan may
discourage or prevent certain types of transactions involving an actual or
potential change in control, which transactions may be beneficial to our
shareholders, by causing substantial dilution to a party that attempts to
acquire us on terms not approved by our Board.

-13-

ABOUT THIS PROSPECTUS

This prospectus is part of a "shelf" registration statement that we
filed with the Securities and Exchange Commission (the "SEC"). By using a shelf
registration statement, we may, from time to time, sell shares of our common
stock in one or more offerings with a maximum aggregate offering price of
$50,000,000. Each time we sell any of our common stock, we will provide a
prospectus supplement that will contain specific information about the offering.
This prospectus and the prospectus supplements provide you with a general
description of the company and our common stock; for further information about
our business and our securities, you should refer to the registration statement,
the reports incorporated by reference in this prospectus, and its exhibits. The
exhibits to our registration statement contain the full text of certain
contracts and other important documents we have summarized in this prospectus.
Since these summaries may not contain all the information that you may find
important in deciding whether to purchase the securities we may offer, you
should review the full text of these documents. The registration statement can
be obtained from the SEC as indicated under the heading "Where You Can Find More
Information."

You should rely only on the information contained or incorporated by
reference in this prospectus and the prospectus supplement. We have not
authorized anyone to provide you with different information. If anyone provides
you with different or inconsistent information, you should not rely on it. We
will not make an offer to sell these securities in any jurisdiction where the
offer or sale is not permitted. You should assume that the information appearing
in this prospectus, as well as information we previously filed with the SEC and
incorporated by reference in this prospectus, is accurate only as of the date on
the front cover of this prospectus. Our business, financial condition, results
of operations and prospects may have changed since that date.

-14-

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

We caution you that this prospectus contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements are based on management's beliefs and assumptions and on
information currently available to management, and use words such as "expect,"
"anticipate," "intend," "plan," "believe," "estimate," "may," "could,"
"possible," "forecast," or similar words and expressions. Forward-looking
statements include information concerning possible or assumed future results of
operations, future product development and related clinical trials and
statements regarding future research and development. Forward-looking statements
are only predictions, and necessarily involve risks and uncertainties and other
factors that may cause the actual results, performance or achievements of
Novavax, or industry results, to be materially different from those anticipated
in the forward-looking statements. These risks and uncertainties are discussed
in the "Risk Factors" section and elsewhere in this prospectus.

-15-

USE OF PROCEEDS

Except as otherwise described in an applicable prospectus supplement, we
currently intend to use the net proceeds from this offering for general
corporate purposes, including but not limited to:

- our internal research and development programs, such as preclinical and
clinical testing and studies of our product candidates and the
development of new technologies,

- pre-launch, marketing, and other expenses related to product candidate
ESTRASORB, if approved by the FDA,

- general working capital, and

- possible future acquisitions of complementary businesses, product lines
or technologies, although no such transactions are currently under
negotiation.

We have not determined the amounts we plan to spend on any of the areas
listed above or the timing of these expenditures, which may vary significantly
depending on various factors such as our research and development results,
regulatory approvals, competition, marketing and sales, and the market
acceptance of any products introduced by us. As a result, our management will
have broad discretion to allocate the net proceeds from this offering. Pending
application of the net proceeds as described above, we intend to invest the net
proceeds of this offering in short-term, interest-bearing, investment-grade
securities.

-16-

PLAN OF DISTRIBUTION

We may sell the securities being offered hereby from time to time in one
or more of the following ways:

- through one or more underwriters,

- through dealers, who may act as agents or principal (including
a block trade in which a broker or dealer so engaged will
attempt to sell the shares as agent but may position and
resell a portion of the block as principal to facilitate the
transaction),

- directly to one or more purchasers,

- through agents,

- in privately negotiated transactions, and

- in any combination of these methods of sale.

We will set forth in a prospectus supplement the terms of the offering of
securities, including:

- the name or names of any agents, underwriters or dealers,

- the purchase price of the common stock being offered and the proceeds we
will receive from the sale,

- any underwriting discounts and commissions or agency fees and other
items constituting underwriters' or agents' compensation,

- any over-allotment options under which underwriters may purchase
additional securities from us, and

- any discounts or concessions allowed or reallowed or paid to dealers.

The distribution of the common stock may be effected from time to time
in one or more transactions at a fixed price or prices, which may be changed, at
market prices prevailing at the time of sale, at prices related to the
prevailing market prices, or at negotiated prices.

Underwriters, dealers and agents that participate in the distribution of
the common stock may be underwriters as defined in the Securities Act of 1933,
as amended (the "Securities Act") and any discounts or commissions they receive
from us and any profit on their resale of the common stock may be treated as
underwriting discounts and commissions under the Securities Act. We will
identify in the applicable prospectus supplement any underwriters, dealers or
agents and will describe their compensation. We may have agreements with
underwriters, dealers and agents to indemnify them against specified civil
liabilities, including liabilities under the Securities Act. Underwriters,
dealers and agents may engage in transactions with or perform services for us in
the ordinary course of their businesses. We have not entered into any
agreements, understandings or arrangements with any underwriters or
broker-dealers regarding the sale of their securities. As of the date of this
prospectus, there are no special selling arrangements between any broker-dealer
or other person and the Company. No period of time has been fixed within which
the shares will be offered or sold.

If required under applicable state securities laws, we will sell the
common stock only through registered or licensed brokers or dealers. In
addition, in some states, we may not sell shares of common stock unless they
have been registered or qualified for sale in the applicable state or unless we
have complied with an exemption from any registration or qualification
requirements.

-17-

AGENTS

We may designate agents who agree to solicit purchases for the period of
their appointment or to sell common stock on a continuing basis. Unless the
prospectus supplement provides otherwise, agents will act on a best efforts
basis for the period of their appointment. Agents may receive compensation in
the form of commissions, discounts or concessions from us. Agents may also
receive compensation from the purchasers of the common stock for whom they sell
as principals. Each particular agent will receive compensation in amounts
negotiated in connection with the sale, which might be in excess of customary
commissions.

UNDERWRITERS

If we use underwriters for a sale of common stock, the underwriters will
acquire the common stock for their own account. The underwriters may resell the
common stock in one or more transactions, including negotiated transactions, at
a fixed public offering price or at varying prices determined at the time of
sale. The obligations of the underwriters to purchase the common stock will be
subject to the conditions set forth in the applicable underwriting agreement.
Unless the prospectus supplement provides otherwise, underwriters will be
obligated to purchase all of the shares of common stock offered by the
prospectus supplement. We may change from time to time any initial public
offering price and any discounts or concessions the underwriters allow or
reallow or pay to dealers. We may use underwriters with whom we have a material
relationship, and we may offer the securities to the public through an
underwriting syndicate or through a single underwriter. We will describe in the
prospectus supplement naming the underwriter the nature of any such relationship
and underwriting arrangement.

DEALERS

We also may sell securities to a dealer as principal. If we sell our
common stock to a dealer as a principal, then the dealer may resell those shares
to the public at varying prices to be determined by such dealer at the time of
resale. The name of the dealer and the terms of the transactions will be set
forth in the applicable prospectus supplement.

DIRECT SALES AND INSTITUTIONAL PURCHASES

We may also sell common stock directly to one or more purchasers, in
which case underwriters or agents would not be involved in the transaction.

Further, we may authorize agents, underwriters or dealers to solicit
offers by certain types of institutional investors to purchase common stock from
us at the public offering price set forth in the prospectus supplement pursuant
to delayed delivery contracts providing for payment and delivery on a specified
date in the future. We will describe the conditions to these contracts and the
commissions we must pay for solicitation of these contracts in the prospectus
supplement.

STABILIZATION ACTIVITIES

Any underwriter may engage in overallotment, stabilizing transactions,
short covering transactions and penalty bids in accordance with Regulation M
under the Exchange Act of 1934, as amended (the "Exchange Act"). Overallotment
involves sales in excess of the offering size, which create a short position.
Stabilizing transactions permit bids to purchase the underlying security so long
as the stabilizing bids do not exceed a specified maximum. Short covering
transactions involve purchases of the common stock in the open market after the
distribution is completed to cover short positions. Penalty bids permit the
underwriters to reclaim a selling concession from a dealer when the common stock
originally sold by the dealer are purchased in a covering transaction to cover
short positions. Those activities may cause the price of the common stock to be
higher than it would otherwise be. If commenced, the underwriters may
discontinue any of the activities at any time. These transactions may be
effected on the Nasdaq Stock Market or otherwise.

-18-

PASSIVE MARKET MAKING

Any underwriters who are qualified market markers on the Nasdaq National
Market may engage in passive market making transactions in the common stock on
the Nasdaq National Market in accordance with Rule 103 of Regulation M, during
the business day prior to the pricing of the offering, before the commencement
of offers or sales of the common stock. Passive market makers must comply with
applicable volume and price limitations and must be identified as passive market
makers. In general, a passive market maker must display its bid at a price not
in excess of the highest independent bid for such security; if all independent
bids are lowered below the passive market maker's bid, however, the passive
market maker's bid must then be lowered when certain purchase limits are
exceeded.

COSTS

We will bear all costs, expenses and fees in connection with the
registration of the common stock, as well as the expense of all commissions and
discounts, if any, attributable to the sales of the common stock by us.

-19-

DESCRIPTION OF OUR CAPITAL STOCK

Our authorized capital stock consists of: (i) 50,000,000 shares of
common stock, par value $.01 per share, of which 30,142,300 shares were
outstanding as of August 8, 2003, and (ii) 2,000,000 shares of preferred stock,
par value $.01 per share, none of which are outstanding.

Our common stock is traded on the Nasdaq National Market under the
symbol NVAX. On August 8, 2003, the closing price of our common stock as
reported on the Nasdaq National Market was $5.66 per share.

COMMON STOCK

Holders of common stock are entitled to one vote for each share held on
all matters submitted to a vote of stockholders and do not have cumulative
voting rights. Accordingly, holders of a majority of the shares of our common
stock entitled to vote in any election of directors may elect all of the
directors standing for election. Holders of our common stock are entitled to
receive ratably such dividends, if any, as may be declared by the Board of
Directors out of funds legally available therefor, subject to any preferential
dividend rights of any outstanding preferred stock. Upon the liquidation,
dissolution or winding up of our Company, the holders of our common stock are
entitled to receive ratably the net assets of our Company available after the
payment of all debts and liabilities and subject to the prior rights of any
outstanding preferred stock. Shares of our common stock are, and the shares
being distributed in this offering will be, when issued, fully paid and
nonassessable. The rights, preferences and privileges of holders of our common
stock are subject, and may be adversely affected by, the rights of holders of
shares of any series of preferred stock which we may designate and issue in the
future.

PREFERRED STOCK

The Board of Directors may, without further action by the stockholders
of our Company, issue preferred stock in one or more series and fix the rights
and preferences thereof, including the dividend rights, dividend rates,
conversion rights, voting rights, pre-emptive rights, terms of redemption
(including sinking fund provisions), redemption prices and liquidation
preferences. Our Amended and Restated Certificate of Incorporation grants the
Board of Directors authority to issue preferred stock and to determine its
rights and preferences without the need for further stockholder approval to
eliminate delays associated with a stockholder vote on specific issuances. The
issue of preferred stock, while providing desirable flexibility in connection
with possible financings, could have the effect of making it more difficult for
a third party to acquire, or of discouraging a third party from acquiring, a
majority of the outstanding voting stock of our Company. We have no present
plans to issue any shares of preferred stock.

OPTIONS AND WARRANTS

The Novavax 1995 Stock Option Plan (the "Plan") was adopted by the Board
of Directors and approved by the stockholders in September, 1995 and will
terminate in 2005. The Plan was amended by resolution of the Board of Directors
adopted in March 1998 and approved by the stockholders in May 1998 to increase
the number of shares as to which options may be granted from 4,000,000 to
4,400,000. The Plan was again amended by resolution of the Board of Directors
adopted in March 2000 and approved by the stockholders in May 2000 to increase
the number of shares as to which options may be granted from 4,400,000 to
6,000,000. The Plan was again amended by resolution of the Board of Directors
adopted in March 2002 and approved by the stockholders in May 2002 to increase
the number of shares as to which options may be granted from 6,000,000 to
8,000,000. Most recently, the Plan was amended by resolution of the Board of
Directors adopted in March 2003 and approved by the stockholders in May 2003 to
increase the number of shares as to which options may be granted from 8,000,000
to 9,000,000.

Options granted under the Plan may be either incentive stock options
within the meaning of Section 422 of the Internal Revenue Code of 1986, as
amended, or options that do not meet the requirements for incentive stock option
treatment, to officers, directors, employees and consultants or advisors to our
Company and any present or future subsidiary to purchase a maximum of 9,000,000
shares of our common stock. As of August 8, 2003, under both this plan and a
prior stock option plan for directors, there were outstanding options to
purchase 4,684,908 shares of our common stock at an average exercise price of
$5.46 per share. There were 1,819,009 shares available for future grant as of
August 8, 2003.

-20-

In addition, we have granted warrants to consultants. At August 8, 2003,
there were outstanding warrants to purchase 70,000 shares of our common stock at
an exercise price of $6.00 per share.

CONVERTIBLE NOTES

We have issued four convertible notes to King Pharmaceuticals, Inc. that
are currently convertible into an aggregate of 5,075,241 shares of our common
stock. The conversion price of each of the notes represents an 18% premium to
the 20 day trading average preceding the agreed-upon lock-in dates prior to the
issuance of each of the notes. The notes carry a 4% coupon payable semi-annually
in cash and stock. The notes allow the Company the option, under certain
circumstances, to pay up to 50% of the interest due in our common stock.

We can require King to convert the notes into our common stock at any
time from January 1, 2002 through December 31, 2004 if the closing price of our
common stock exceeds 180% of the conversion price then in effect for at least 30
trading days in any period of 45 consecutive trading days. After December 31,
2004, we can redeem the notes at 102%, 101% and 100% of face value during the
years ended December 31, 2005, 2006 and 2007, respectively.

SHAREHOLDER RIGHTS PLAN

We have adopted a Shareholder Rights Plan pursuant to which the Board of
Directors declared a dividend distribution of one preferred stock purchase right
for each outstanding share of common stock. Each right, once exercisable,
entitles the holder to purchase from us one one-thousandth (1/1,000th) of a
share of Series D Junior Participating Preferred Stock (the "Preferred Stock"),
at a price of $40.00, subject to certain adjustments.

The rights, unless earlier redeemed by the Board, become exercisable
upon the close of business on the day which is the earlier of (i) the tenth
business day following a public announcement that a person or group of
affiliated or associated persons (with certain exceptions) has acquired
beneficial ownership of 15% or more of the outstanding voting stock of the
Company, and (ii) the tenth business day after the date of the commencement by
any person of a tender or exchange offer, the consummation of which would result
in such person or group of affiliated or associated persons becoming an
"acquiring person" as defined in the rights plan. The rights expire at the close
of business on August 7, 2012, unless earlier redeemed or exchanged by us as
described below.

Unless the rights are earlier redeemed, in the event that a person or
group becomes an "acquiring person," the rights plan provides that proper
provisions will be made so that each holder of record of a right (other than
rights beneficially owned by an acquiring person and certain of its affiliates,
associates and transferees) will thereafter have the right to receive, upon
payment of the exercise price, that number of shares of the Preferred Stock
having a fair market value determined in accordance with the rights plan at the
time of the transaction equal to approximately two times the exercise price
(such value to be determined with reference to the fair market value of our
common stock as provided in the rights plan).

In addition, unless the rights are earlier redeemed or exchanged, in the
event that, after the time that a person or group becomes an acquiring person,
we were to be acquired in a merger or other business combination (in which any
shares of common stock are changed into or exchanged for other securities or
assets) or more than 50% of the assets or earning power of the Company and its
subsidiaries (taken as a whole) were to be sold or transferred in one or a
series of related transactions, the rights plan provides that proper provision
will be made so that each holder of record of a right (other than rights
beneficially owned by an acquiring person and certain of its affiliates,
associates and transferees) will have the right to receive, upon payment of the
exercise price, that number of shares of common stock of the acquiring company
having a fair market value at the time of such transaction determined in
accordance with the rights plan equal to approximately two times the exercise
price.

At any time after any person or group becomes an acquiring person and
prior to the acquisition by such person or group of 50% or more of the
outstanding voting stock, the Board may exchange the rights, in whole or in
part, for that number of shares of the Preferred Stock having a fair market
value on the date such person or group became an acquiring person equal to the
excess of (i) the fair market value of Preferred Stock issuable upon the
exercise of the rights over (ii) the exercise price of the rights, in each case
subject to anti-dilution adjustments.

-21-

At any time prior to the close of business on the tenth business day
after there has been a public announcement that a person has become an acquiring
person or such earlier date as a majority of the Board shall become aware of the
existence of an acquiring person, we may redeem the rights in whole, but not in
part, at a price of $.001 per right. Immediately upon the effective time of such
Board action, the right to exercise the rights will terminate and the only right
of the holders will be to receive the redemption price.

For as long as the rights are then redeemable, we may, except with
respect to the redemption price, amend the rights in any manner, including
extending the time period in which the rights may be redeemed. At any time when
the rights are not then redeemable, we may amend the rights in any manner that
does not materially adversely affect the interests of holders of the rights as
such.

TRANSFER AGENT

Our registrar and transfer agent for all shares of common stock is
Equiserve, 150 Royall Street, Canton, MA 02021.

DIVIDEND POLICY

We have never paid cash dividends on our common stock. We currently
anticipate that we will retain all of our earnings for use in the development of
our business and do not anticipate paying any cash dividends in the foreseeable
future.

LEGAL MATTERS

Certain legal matters with respect to the shares of common stock offered
hereby have been passed upon by White White & Van Etten LLP, 55 Cambridge
Parkway, Cambridge, Massachusetts 02142. David A. White, a partner of such firm,
owns 50,000 shares of our common stock.

EXPERTS

Ernst & Young LLP, independent auditors, have audited our consolidated
financial statements included in our Annual Report on Form 10-K for the year
ended December 31, 2002, as set forth in their report, which is incorporated by
reference in this prospectus and elsewhere in the registration statement. Our
financial statements are incorporated by reference in reliance on Ernst & Young
LLP's report, given on their authority as experts in accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION

We are subject to the informational requirements of the Exchange Act,
and in accordance with the Exchange Act we file reports and other information
with the SEC. These reports and other information are not incorporated by
reference in this prospectus and do not form a part of this prospectus except as
stated below under "Incorporation of Certain Information by Reference." You may
read and copy these reports and other information filed with the SEC at the
SEC's Public Reference Room located at 450 Fifth Street, N.W., Washington, D.C.
You can request copies of these documents, for a copying fee, by writing to the
SEC. Please call the SEC at 1-800-SEC-0330 or visit the SEC's website for more
information about the operation of the public reference rooms. Our filings with
the SEC are also available to you over the Internet at the SEC's web site at
http://www.sec.gov.

Our common stock is traded as "National Market Securities" on the Nasdaq
National Market under the symbol NVAX. Materials we file can also be inspected
at the offices of Nasdaq Operations at 1735 K Street, Washington, D.C. 20006.

We have filed a registration statement on Form S-3 (together with all
amendments and exhibits, which we refer to as the registration statement) with
the SEC under the Securities Act with respect to the common shares offered by
this prospectus. This prospectus, which constitutes a part of the registration
statement, does not contain all the information in the registration statement.
For further information about us and our securities, see the registration

-22-

statement and its exhibits. Statements made in this prospectus as to the content
of any contract, agreement or other document are not necessarily complete. With
respect to each such contract, agreement or other document filed as an exhibit
to the registration statement, reference is made to the exhibit for a more
complete description of the matter involved, and each such statement shall be
deemed qualified in its entirety by such reference.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

The SEC allows us to "incorporate by reference" the information we file
with it, which means that we can disclose important information to you by
referring you to those documents. This prospectus is part of a registration
statement we filed with the SEC. You should rely on the information incorporated
by reference in this prospectus and the registration statement. The information
incorporated by reference is considered to be part of this prospectus and
information we file later with the SEC will automatically update and supersede
this information. We incorporate by reference the documents listed below and any
future filings made with the SEC under Section 13(a), 13(c), 14 or 15(d) of the
Exchange Act until the selling stockholders sell all of their shares of common
stock or the offering is otherwise terminated. The documents we are
incorporating by reference are:

1. Our Annual Report on Form 10-K for the fiscal year ended
December 31, 2002, as filed with the SEC on March 28, 2003;

2. Quarterly Reports on Form 10-Q for the quarters ended:

a. March 31, 2003, as filed with the SEC on May 15, 2003;
b. June 30, 2003, as filed with the SEC on August 13, 2003;
and
c. September 30, 2003, as filed with the SEC on November
12, 2003.

3. Current Reports on Form 8-K filed with the SEC on May 14, 2003
and August 8, 2003;

4. Definitive Proxy Statement with respect to the Annual Meeting of
Stockholders held on May 7, 2003, as filed with the SEC on March
31, 2003;

5. The description of our common stock contained in the
Registration Statement on Form 10 filed with the SEC on
September 14, 1995; and

6. All other reports filed by us under Section 13(a) or 15(d) of
the Exchange Act since the end of our fiscal year ended December
31, 2002.

You may request a copy of these filings at no cost by writing or
telephoning our chief financial officer at the following address and telephone
number: Novavax, Inc., 8320 Guilford Road, Columbia, MD 21046; (301) 854-3900.
Attn: Dennis Genge.

We undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise.
You are advised, however, to consult any further disclosures we make on related
subjects in our 10-Q, 8-K and 10-K reports to the SEC. Also note that we provide
a cautionary discussion of risks and uncertainties relevant to our business in
the "Risk Factors" section of this prospectus. These are factors that we think
could cause our actual results to differ materially from expected results. Other
factors besides those listed here could also adversely affect us. This
discussion is provided as permitted by the Private Securities Litigation Reform
Act of 1995.

-23-

================================================================================

4,000,000 SHARES

NOVAVAX, INC.

COMMON STOCK

-----------------------

PROSPECTUS SUPPLEMENT

-----------------------

LANE CAPITAL MARKETS

JUNE 30, 2005

================================================================================